Cancer treatment has been transformed over the past two decades by a fundamental shift in approach: from treating cancer by where it is in the body to treating it by what's driving it at the genetic level. This shift — enabled by advances in genomic sequencing and targeted therapy development — has produced some of the most significant improvements in cancer survival rates in medical history.
The Genetic Basis of Cancer
Cancer is fundamentally a disease of the genome. It arises when mutations accumulate in genes that control cell growth, division, and death. These mutations can be inherited (germline mutations, present in every cell from birth) or acquired (somatic mutations, arising in specific cells during a person's lifetime). Understanding which mutations are driving a specific cancer allows oncologists to select treatments that target those specific vulnerabilities.
Key Genetic Breakthroughs in Cancer Treatment
EGFR-Targeted Therapy in Lung Cancer
Mutations in the EGFR gene are found in approximately 15% of non-small cell lung cancers (NSCLC) in Western populations and up to 50% in Asian populations. EGFR inhibitors like erlotinib, gefitinib, and osimertinib have transformed outcomes for EGFR-mutant NSCLC, with response rates far exceeding traditional chemotherapy.
HER2-Targeted Therapy in Breast Cancer
HER2 amplification occurs in approximately 20% of breast cancers and was historically associated with poor prognosis. Trastuzumab (Herceptin) and subsequent HER2-targeted agents have dramatically improved survival in HER2-positive breast cancer, turning a poor-prognosis subtype into one of the most treatable.
BRCA1/2 and PARP Inhibitors
BRCA1 and BRCA2 mutations impair DNA repair. PARP inhibitors (olaparib, niraparib, rucaparib) exploit this vulnerability by blocking an alternative DNA repair pathway, causing cancer cells with BRCA mutations to die while sparing normal cells. FDA-approved for BRCA-mutant breast, ovarian, prostate, and pancreatic cancers.
Immunotherapy and PD-L1 Expression
Checkpoint inhibitors (pembrolizumab, nivolumab) work by releasing the brakes on the immune system's ability to attack cancer cells. PD-L1 expression and tumor mutational burden (TMB) are genetic biomarkers that predict response to immunotherapy across multiple cancer types.
BCR-ABL and Imatinib in CML
The BCR-ABL fusion gene, caused by the Philadelphia chromosome translocation, drives chronic myeloid leukemia (CML). Imatinib (Gleevec) — the first targeted cancer therapy — specifically inhibits BCR-ABL, transforming CML from a fatal disease into a manageable chronic condition.
The Role of Comprehensive Genomic Profiling
Comprehensive genomic profiling (CGP) of tumor tissue identifies all actionable mutations in a cancer, enabling oncologists to match patients to targeted therapies and clinical trials. As the number of FDA-approved targeted therapies grows, CGP is becoming standard of care for many advanced cancers.
FAQs
How do I know if my cancer has actionable genetic mutations?
Tumor genomic profiling — performed on a biopsy sample — can identify actionable mutations. Ask your oncologist about comprehensive genomic profiling if you have advanced cancer.
Can germline genetic testing help with cancer treatment?
Yes. Germline mutations like BRCA1/2 not only guide treatment decisions (PARP inhibitors) but also have implications for family members who may carry the same mutation and benefit from preventive screening.
Know Your Inherited Cancer Risk — Before Symptoms Appear
MapmyGenome's cancer genetic testing panels — including BRCA Map and DNA OncoScreen — identify inherited gene mutations associated with cancer risk, backed by NABL-certified labs and expert genetic counsellors who help you build a personalised prevention and monitoring plan.
